



*Case Report*

---

**Case Report Primary Alveolar Rhabdomyosarcoma of the Breast in  
an Adult: An Extremely Rare Case**

O,SIYOURI<sup>1\*</sup>, J,CHOUEF<sup>2</sup>, H,EL HILALI<sup>3</sup>, S,ELHAKYM<sup>4</sup>, C,CHBIHI<sup>5</sup>, L,AMAADOUR<sup>6</sup>,  
K,OUALLA<sup>7</sup>, Z,BENBRAHIM<sup>8</sup>, S,ARIFT<sup>9</sup>, N,MELLAS<sup>10</sup>

**\*Correspondence to:** Siyouri Oumaima, Department of Oncology, Morocco.

**Copyright.**

© 2024 **Siyouri Oumaima**. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 30 July 2024

Published: 01 August 2024

**Abstract**

*Background: Primary breast sarcoma (PBS) is rare, comprising approximately 1% of breast malignancies. Rhabdomyosarcoma (RMS) accounts for an extremely small proportion of PBSs, often leading to delayed histologic confirmation. RMS is common in children and adolescents and rare in adults. Primary RMS arising from the breast is exceedingly rare in adults. We report a case of a primary RMS of the breast in a 18 year-old woman, who presented in an advanced stage.*

*Key Words: alveolar rhabdomyosarcoma; Primary sarcoma of the breast*

**Introduction**

Rhabdomyosarcoma (RMS), the most common pediatric soft tissue tumor, rarely occurs in the adult population. It represents less than 3% of all adult primary soft tissue sarcomas. The breast is an exceedingly rare primary site of occurrence and occurs mainly in children. We present here a case of alveolar, which was treated in our Cancer Institute according to the IRS III (Intergroup Rhabdomyosarcoma Study) protocol. To better understand the clinicopathological characteristics of these rare conditions, we searched and reviewed the literature related to this disease.

**Case Presentation/Methods**

Our Patient was a 18-year-old girl, who had a 10-cm mass in her left breast. Imaging examination at an outside hospital revealed a breast mass and multiple metastatic lesions in the lumbar spine and left axillary lymph nodes. She underwent core needle biopsy of the breast mass; the tumor was diagnosed as aRMS. After receiving the first neoadjuvant chemotherapy cycle, she was referred to our center and continued to receive the treatment for 8 cycles. However, MRI showed no change in the status of the left breast and metastatic masses. The patient underwent palliative mastectomy. The surgical specimen consisted of a lump of breast tissue that measured 9.5× 8.5×4 cm and weighed 114 g. A well-demarcated lobulating soft mass measuring 4×2.5×2 cm was identified in the breast parenchyma; the resection margins were clear. The mass was composed of nests and sheets of primitive round cells separated by fibrous septa. These nests exhibited a

central loss of cellular cohesion. IHC staining of the tumor cells yielded positive results for desmin, CD56, and myogenin and negative results for CK AE/AE3 and SMA. PAX3-FKHR (FOXO1) fusion transcripts [t(2;13)(q35;q14)] were identified using nested RT-PCR, supporting the diagnosis of aRMS. Post-surgery, she received eight chemotherapy cycles (carboplatin, VP-16, and ifosfamide), which was interrupted by fungal infection and low platelet counts. Followup imaging examination revealed recurrence of the chest wall mass and exacerbation of the multifocal bone metastasis with bone marrow involvement. The patient died due to respiratory suppression 22-month post-diagnosis.

## Discussions

PBSs are a group of mesenchymal-derived de novo malignancies, accounting for less than 1% of breast cancer.<sup>4,10</sup> Due to their rarity, large scale analyses have been limited, and PBS has no known etiology.<sup>4,11</sup> Some breast sarcomas are related with previous treatment (radiation therapy, therapy-associated chronic lymphedema and variable chemicals), and they are categorized as secondary breast sarcoma.<sup>4,11,12</sup> Thus far, angiosarcoma is the most commonly reported PBS; virtually any type of sarcoma can occur in the breast as a PBS.<sup>13</sup> Based on our 18-year institutional experience, angiosarcoma is the most common type of PBS, followed by extra-skeletal osteosarcoma and liposarcoma. However, the distribution of PBS subtypes is not consistent across age groups; angiosarcomas were mostly found in middle-aged women (age, 40 to 60 years). Among young females (age, 10 to 30 years), angiosarcoma was rare. RMS was the most common subtype of PBS in this age group. Only 26 cases of RMS of breast origin have been reported in English literature, almost exclusively in the young females.<sup>7</sup> Among the 29 cases, aRMS was the most common type (n= 17, 59%), followed by eRMS (n=6, 21%), ssRMS (n=2, 7%), and pleomorphic RMS (n=1, 3%). Subtype-related information was not available for three cases (n=3, 10%). All cases involved female patients; median age was 16.4 years (range, 11 to 60 years). Majority of the cases involved adolescents and young adults (range, 10 to 30 years; 24 cases, 83%); five cases (19.2%) involved middle-aged patients. All but one aRMS cases involved teenage girls; contrastingly, eRMS cases were almost equally distributed between adolescents and middle-aged women; the other RMS types mostly involved middle-aged patients. Interestingly, aRMS cases frequently presented with axillary lymphadenopathy, mimicking mammary carcinomas. To the best of our knowledge, the ssRMS case in this series is the second to be reported in the literature. ssRMS is a newly classified subtype that accounts for 5%–10% of all RMS cases; it mostly involves paratesticular lesions in pediatric populations and head and neck and genitourinary lesions in adults.<sup>8</sup> As ssRMS was defined as a variant of eRMS, we reviewed all reports of eRMS for reclassification; however, none of the eRMS cases had

---

the histological characteristics that indicated ssRMS. Differential diagnoses vary according to RMS subtype, however, differentiation of malignant phyllodes tumor (MPT) with sarcomatous overgrowth is always important regardless of subtypes.<sup>2</sup> Age can be used to differentiate these malignancies; most MPTs occur in the fifth or sixth decade of life, whereas primary RMS of the breast mainly affects young patients.<sup>3,14,15</sup> Extensive tissue sampling is necessary, especially in middle-aged patients, as the epithelial component of the MPT can be very small.<sup>2</sup> IHC results are critical after excluding MPT with sarcomatous overgrowth; single staining or a combination of desmin, MyoD1, and myogenin staining have been used to diagnose RMS. However, Parham et al.<sup>16</sup> suggested that desmin should always be used as part of a panel and never as a sole diagnostic marker, as it can non-specifically stain other small round cells and smooth muscle cells. However, despite positive IHC results, the possibility of other myogenic neoplasms cannot be excluded in some cases; therefore, genetic analysis is useful for both histological typing and diagnosis.<sup>8</sup> Two characteristic cytogenetic changes—  $t(2;13)(q35;q14)$  resulting in PAX3-FKHR (FOXO1) fusion and  $t(1;13)(p13;q14)$  resulting in PAX7-FKHR (FOXO1) fusion— are identified in about 80% of aRMS cases, which allow aRMS to be distinguished from other types of round cell neoplasms and RMS.<sup>8</sup> These fusions are known to be associated with the activation of transcription from PAX3/PAX7-binding sites and to contribute to tumorigenesis.<sup>17</sup> In the D9803 COG study, failure-free survival of fusion-positive aRMS patients was lower than that of fusion-negative patients, and PAX3-FKHR (FOXO1) fusion-positive patients showed higher overall survival than PAX7-FKHR (FOXO1) fusion-positive patients.<sup>17</sup> Due to its rarity, definite treatment has not been established for RMS of the breast. Generally, axillary dissection of PBS is not recommended as sarcoma usually does not metastasize to lymph nodes; axillary dissection is only required in cases involving palpable lymphadenopathy. However, more than 50% of breast aRMS cases (12/17 cases, 71%) showed axillary node metastasis; moreover, 58% of these cases had no disseminated metastases (7/12 cases). These findings might suggest that axillary node metastasis of aRMS is not only incidental findings of disseminated metastasis, but also early event of disease spreading. Therefore, axillary node dissection or sentinel node sampling of aRMS needs to be considered in cases that require surgery.

## Conclusion

RMS of the breast is an aggressive malignancy. Although very rare, it has to be thought of, as one of differential diagnoses, particularly in adolescent females. Small round cell malignancy in the breasts of young females should be suspected for the possibility of primary or secondary RMS. Although cytology is efficient in diagnosing small round cell tumors, a high index of suspicion, good knowledge of the cytological criteria

in conjunction with clinical and radiological findings and immunochemical stains are prerequisites for the correct diagnosis. Histopathology remains the means for the definitive diagnosis and formulation of treatment plan.

## References

1. Lim SZ, Ong KW, Tan BK, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. *J Clin Pathol* 2016; 69: 373-81.
2. Hicks DG, Lester SC. *Diagnostic pathology: breast*. 2nd ed. Salt Lake City: Saunders-Elsevier, 2016; 496-577.
3. Chugh R, Baker L. Nonepithelial malignancies of the breast. *Oncology (Williston Park)* 2004; 18: 665-73.
4. Yin M, Mackley HB, Drabick JJ, Harvey HA. Primary female breast sarcoma: clinicopathological features, treatment and prognosis. *Sci Rep* 2016; 6: 31497.
5. Attili VS, Dadhich HK, Ramarao C, Bapsy PP, Ramachandra C, Anupama G. A case of primary rhabdomyosarcoma of the breast. *Indian J Surg* 2007; 69: 201-2.
6. Kebudi R, Koc BS, Gorgun O, Celik A, Kebudi A, Darendeliler E. Breast metastases in children and adolescents with rhabdomyosarcoma: a large single-institution experience and literature review. *J Pediatr Hematol Oncol* 2017; 39: 67-71.
7. Audino AN, Setty BA, Yeager ND. Rhabdomyosarcoma of the breast in adolescent and young adult (AYA) women. *J Pediatr Hematol Oncol* 2017; 39: 62-6.
8. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. *WHO classification of tumors of soft tissue and bone*. 4th ed. Lyon: International Agency for Research on Cancer, 2013; 127-36.
9. Rasinariu A, Andreiuolo F, Terrier P, Balleyguier C, Delaloue S, Vielh P. Primary spindle rhabdomyosarcoma of the breast in an adult female. *Cytopathology* 2011; 22: 137-9.
10. Kim DY, Seol YM, Kim H, Kim A, Choi YJ. Primary rhabdomyosarcoma of the breast in a 17-year-old girl: case report. *Medicine (Baltimore)* 2017; 96: e9076.
11. Bland KI, Klimberg VS, Copeland E, Gradishar WJ. *The breast: comprehensive management of benign and malignant disease*. 5th ed. Philadelphia: Saunders-Elsevier, 2018; 156-68.
12. Li N, Cusido MT, Navarro B, et al. Breast sarcoma: a case report and review of literature. *Int J Surg Case Rep* 2016; 24: 203-5.
13. Schnitt SJ, Collins LC. *Biopsy interpretation of the breast*. 2nd ed. Philadelphia: Lippincott Williams &

---

Wilkins, 2013; 416-7.

14. Italiano A, Largillier R, Peyrottes I, Hannoun-Levy JM, Lallement M, Thyss A. Primary embryonal rhabdomyosarcoma of the breast in an adult female. *Breast J* 2005; 11: 214.

15. Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. *Surg Oncol* 2003; 12: 27-37.

16. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. *Arch Pathol Lab Med* 2006; 130: 1454-65.

17. Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. *Adv Anat Pathol* 2013; 20: 387-97.

18. Hays DM, Donaldson SS, Shimada H, et al. Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. *Med Pediatr Oncol* 1997; 29: 181-9.

19. Herrera LJ, Lugo-Vicente H. Primary embryonal rhabdomyosarcoma of the breast in an adolescent female: a case report. *J Pediatr Surg* 1998; 33: 1582-4.

20. Binokay F, Soyupak SK, Inal M, Celiktas M, Akgul E, Aksungur E. Primary and metastatic rhabdomyosarcoma in the breast: report of two pediatric cases. *Eur J Radiol* 2003; 48: 282-4. 21. Vishnevskaiia Ia V, Sharoev TA, Stepanova EV, Osipova LV. Rhabdomyosarcoma of the breast in girls. *Arkh Patol* 2004; 66: 47-51.

22. Dausse F, Balu-Maestro C, Chapellier C, Leblanc-Talent P. Rhabdomyosarcoma of the breast. *Clin Imaging* 2005; 29: 337-41.

23. Nogi H, Kobayashi T, Kawase K, et al. Primary rhabdomyosarcoma of the breast in a 13-year-old girl: report of a case. *Surg Today* 2007; 37: 38-42.

24. Valera ET, Brassesco MS, Muglia VF, Scrideli CA, Tone LG. Alveolar rhabdomyosarcoma with breast involvement. *Chin Med J (Engl)* 2013; 126: 998.

25. Bhosale SJ, Kshirsagar AY, Sulhyan SR, Sulhyan SR. Rhabdomyosarcoma of the breast: a rare malignancy. *Am J Case Rep* 2013; 14: 250-2.

26. Mondal SK, Mandal PK, Adhikari A, Basak B. Primary pleomorphic rhabdomyosarcoma of breast: report of a rare neoplasm. *J Res Med Sci* 2014; 19: 1200-2.

27. Kallianpur AA, Praveen, Shukla NK, Deo SV, Khanna P, Durgapal P. Primary mammary rhabdomyosarcoma in a nineteen year old female: a case report and review of literature. *Indian J Cancer* 2015; 52: 295-6.

- 
28. Pareekutty NM, Bhagat M, Vora T, Qureshi SS. Rhabdomyosarcoma of the breast: report of two cases with the review of literature. *J Indian Assoc Pediatr Surg* 2016; 21: 81-3.
29. Yuan Y, Hou J, Pan Y. Rhabdomyosarcoma of the breast: report of a rare malignancy. *Cancer Biol Ther* 2017; 18: 676-80.
30. Bayramoglu Z, Kebudi R, Yilmaz R, et al. Primary rhabdomyosarcoma of the breast: imaging findings and literature review. *Breast Care (Basel)* 2018; 13: 293-7. 31. Jean-Louis CJ. Alveolar rhabdomyosarcoma of the breast in adolescent female. *Am Surg* 2018; 84: e352-3.



Medtronic